Omeros Corporation (NASDAQ:OMER – Get Free Report) CAO David Borges sold 10,000 shares of Omeros stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $18.95, for a total value of $189,500.00. Following the completion of the sale, the chief accounting officer owned 5,906 shares of the company’s stock, valued at $111,918.70. The trade was a 62.87% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Omeros Stock Down 0.2%
OMER traded down $0.04 during midday trading on Tuesday, hitting $19.28. 1,314,611 shares of the company traded hands, compared to its average volume of 1,716,966. The firm has a market capitalization of $1.40 billion, a PE ratio of 15.06 and a beta of 2.54. The company’s 50-day moving average is $11.93 and its 200 day moving average is $11.81. Omeros Corporation has a 52 week low of $3.94 and a 52 week high of $19.65.
Omeros (NASDAQ:OMER – Get Free Report) last announced its quarterly earnings results on Thursday, August 13th. The biopharmaceutical company reported $0.02 EPS for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.29. The company had revenue of $28.53 million during the quarter, compared to the consensus estimate of $12.69 million. On average, sell-side analysts predict that Omeros Corporation will post -0.37 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Omeros
Wall Street Analysts Forecast Growth
A number of equities research analysts have commented on OMER shares. HC Wainwright reaffirmed a “buy” rating on shares of Omeros in a research report on Monday, July 27th. Zacks Research downgraded Omeros from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 13th. Wall Street Zen raised Omeros from a “hold” rating to a “buy” rating in a report on Saturday, August 15th. Finally, Weiss Ratings raised Omeros from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, Omeros presently has a consensus rating of “Moderate Buy” and a consensus target price of $38.00.
View Our Latest Stock Analysis on OMER
About Omeros
Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.
Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.
Featured Articles
- Five stocks we like better than Omeros
- Pathward’s Credit Scare Tests Its Comeback Story
- Wiring the AI Boom: Rumble’s $13.7B Pivot
- StoneX: Too Far Too Fast?
- DICK’s Sporting Goods Faces Pain Now for a Bigger Prize
Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.
